Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 07 2024 - 4:05PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage
precision oncology company focused on the treatment and prevention
of virus-associated cancers that impact patients worldwide, today
announced that Mark Rothera, President and Chief Executive Officer,
and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are
scheduled to participate in a fireside chat at the RBC Capital
Markets Global Healthcare Conference on Tuesday, May 14, 2024, at
11:00 a.m. EDT.
A live webcast of the presentation will be
available on the Investors section of the Viracta website under
"Events and Webcasts" and archived for 90 days.
About Viracta Therapeutics,
Inc.Viracta is a clinical-stage precision oncology company
focused on the treatment and prevention of virus-associated cancers
that impact patients worldwide. Viracta’s lead product candidate is
an all-oral combination therapy of its proprietary investigational
drug, nanatinostat, and the antiviral agent valganciclovir
(collectively referred to as Nana-val). Nana-val is currently being
evaluated in multiple ongoing clinical trials, including a pivotal,
global, multicenter, open-label Phase 2 basket trial for the
treatment of multiple subtypes of relapsed or refractory (R/R)
Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 clinical trial for the
treatment of patients with recurrent or metastatic (R/M) EBV+
nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid
tumors. Viracta is also pursuing the application of its “Kick and
Kill” approach in other EBV-related diseases.
For additional information, please visit
www.viracta.com.
Investor Relations
Contact:Ashleigh BarretoHead of Investor Relations &
Corporate CommunicationsViracta Therapeutics,
Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Nov 2023 to Nov 2024